| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marcello D Bronstei. Optimizing acromegaly treatment. Frontiers of hormone research. vol 38. 2010-09-07. PMID:20616509. |
many efficacious therapeutic approaches are currently available to acromegaly control, namely pituitary surgery, radiotherapy and medical therapy, which encompasses dopamine agonists (da), somatostatin analogs (sa; currently considered the gold standard treatment) and the gh-receptor antagonist pegvisomant (peg-v). |
2010-09-07 |
2023-08-12 |
Not clear |
| Roberto Salvatori, Lisa B Nachtigall, David M Cook, Vivien Bonert, Mark E Molitch, Sandra Blethen, Stephen Chan. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary. vol 13. issue 2. 2010-08-17. PMID:19898989. |
surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. |
2010-08-17 |
2023-08-12 |
Not clear |
| Roberto Salvatori, Lisa B Nachtigall, David M Cook, Vivien Bonert, Mark E Molitch, Sandra Blethen, Stephen Chan. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary. vol 13. issue 2. 2010-08-17. PMID:19898989. |
fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-naïve or not currently taking long-acting octreotide ("other"; n = 26). |
2010-08-17 |
2023-08-12 |
Not clear |
| Erlick A C Pereira, Martin R Turner, John A H Wass, Kevin Talbo. Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. vol 11. issue 1-2. 2010-08-02. PMID:19634028. |
concern therefore arose in our case that treatment of the acromegaly with a somatostatin analogue might adversely affect the natural course of his als through lowering of potentially beneficial igf-1 levels. |
2010-08-02 |
2023-08-12 |
mouse |
| Phillip Kelly, Kathy T Maher, Shern L Chew, John P Monson, Ashley B Grossman, Paul J Jenkin. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 16. issue 2. 2010-06-24. PMID:19833584. |
to evaluate the efficacy of lanreotide autogel, a depot preparation of a long-acting somatostatin analogue, in patients with acromegaly who were previously treated with octreotide. |
2010-06-24 |
2023-08-12 |
Not clear |
| A Colao, G Lombard. Dose optimization of somatostatin analogues for acromegaly patients. Journal of endocrinological investigation. vol 33. issue 2. 2010-06-24. PMID:20348838. |
dose optimization of somatostatin analogues for acromegaly patients. |
2010-06-24 |
2023-08-12 |
Not clear |
| T R Bandgar, V Sarathi, V Shivane, N Bansode, P S Menon, N S Sha. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. Journal of postgraduate medicine. vol 56. issue 1. 2010-06-10. PMID:20393242. |
the value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. |
2010-06-10 |
2023-08-12 |
Not clear |
| T R Bandgar, V Sarathi, V Shivane, N Bansode, P S Menon, N S Sha. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. Journal of postgraduate medicine. vol 56. issue 1. 2010-06-10. PMID:20393242. |
the usefulness of the acute octreotide test in the selection of patients with acromegaly for chronic somatostatin depot analogues treatment is controversial. |
2010-06-10 |
2023-08-12 |
Not clear |
| Gherardo Mazziotti, Andrea Giustin. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. vol 13. issue 1. 2010-05-13. PMID:19189218. |
long-acting somatostatin analogs (ssa) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50-75% of the patients. |
2010-05-13 |
2023-08-12 |
Not clear |
| Shlomo Melmed, David Cook, Jochen Schopohl, Miklos I Goth, Karen S L Lam, Josef Mare. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. vol 13. issue 1. 2010-05-13. PMID:19639415. |
the study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release autogel formulation of the somatostatin analogue lanreotide (lan-autogel) in unselected patients with acromegaly. |
2010-05-13 |
2023-08-12 |
Not clear |
| Renata S Auriemma, Mariano Galdiero, Ludovica F S Grasso, Pasquale Vitale, Alessia Cozzolino, Gaetano Lombardi, Annamaria Colao, Rosario Pivonell. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. European journal of endocrinology. vol 162. issue 5. 2010-05-07. PMID:20156970. |
somatostatin analogs (sa) are the cornerstone in the medical treatment of acromegaly, used as either primary or adjunctive therapy. |
2010-05-07 |
2023-08-12 |
Not clear |
| Jan Bornschein, Ignat Drozdov, Peter Malfertheine. Octreotide LAR: safety and tolerability issues. Expert opinion on drug safety. vol 8. issue 6. 2010-02-17. PMID:19998528. |
somatostatin analogues are the cornerstone in therapy of acromegaly and functioning neuroendocrine tumors. |
2010-02-17 |
2023-08-12 |
Not clear |
| Ana Paula M Casarini, Raquel S Jallad, Emília M Pinto, Iberê C Soares, Suely Nonogaki, Daniel Giannella-Neto, Nina R Musolino, Venâncio A F Alves, Marcello D Bronstei. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary. vol 12. issue 4. 2010-02-01. PMID:19330452. |
acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. |
2010-02-01 |
2023-08-12 |
Not clear |
| G N Ajay Thankamony, David B Dunger, Carlo L Acerin. Pegvisomant: current and potential novel therapeutic applications. Expert opinion on biological therapy. vol 9. issue 12. 2010-01-26. PMID:19916734. |
it is currently licensed for the treatment of acromegaly where surgery and medical therapy with somatostatin analogues have failed. |
2010-01-26 |
2023-08-12 |
Not clear |
| Richard A Feelders, Leo J Hofland, Maarten O van Aken, Sebastian J Neggers, Steven W J Lamberts, Wouter W de Herder, Aart-Jan van der Lel. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. vol 69. issue 16. 2009-12-29. PMID:19852525. |
medical therapy of acromegaly: efficacy and safety of somatostatin analogues. |
2009-12-29 |
2023-08-12 |
Not clear |
| Richard A Feelders, Leo J Hofland, Maarten O van Aken, Sebastian J Neggers, Steven W J Lamberts, Wouter W de Herder, Aart-Jan van der Lel. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. vol 69. issue 16. 2009-12-29. PMID:19852525. |
new developments in the medical therapy of acromegaly include the universal somatostatin receptor agonist pasireotide, which has a broader affinity for all somatostatin receptor (sst) subtypes compared with the currently available somatostatin analogues with preferential affinity for the sst2 receptor, and chimeric compounds that interact with both somatostatin and dopamine receptors with synergizing effects on gh secretion. |
2009-12-29 |
2023-08-12 |
Not clear |
| S W Lamberts, E P Krenning, J G Klijn, J C Reub. Clinical applications of somatostatin analogs. Trends in endocrinology and metabolism: TEM. vol 1. issue 3. 2009-12-11. PMID:18411107. |
the somatostatin analog sandostatin is successfully used in the treatment of metastatic endocrine pancreatic tumors, carcinoids, and acromegaly. |
2009-12-11 |
2023-08-12 |
Not clear |
| F Castinetti, A Saveanu, I Morange, T Bru. Lanreotide for the treatment of acromegaly. Advances in therapy. vol 26. issue 6. 2009-12-11. PMID:19533047. |
the drug shows high binding affinity for somatostatin receptors, sstr2 and sstr5, which is the primary mechanism considered to be responsible for decreasing gh secretion and gh cell proliferation in acromegaly. |
2009-12-11 |
2023-08-12 |
Not clear |
| B L Herrmann, M Severing, A Schmermund, C Berg, Th Budde, R Erbel, K Man. Impact of disease duration on coronary calcification in patients with acromegaly. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 117. issue 8. 2009-12-09. PMID:19373755. |
the prospective study included 30 patients with acromegaly (mean age 53+/-14 year; 16 females, 14 males; bmi 28.1+/-3.6 kg/m (2); mean+/-sd), 12 patients had active disease (igf-1 751+/-338 microg/l; gh 25.6+/-36.4 microg/l), 9 were well-controlled (igf-1 157+/-58 microg/l; gh 1.8+/-1.1 microg/l) under somatostatin analogue octreotide (n=5), dopamine agonists (n=2), and the gh receptor antagonist pegvisomant (n=2; gh levels were not determined in this subgroup) and 9 were cured igf-1 (148+/-57 microg/l; gh 0.5+/-0.2 microg/l). |
2009-12-09 |
2023-08-12 |
Not clear |
| Sebastian J C Neggers, Aart Jan van der Lel. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nature reviews. Endocrinology. vol 5. issue 10. 2009-11-23. PMID:19763127. |
somatostatin analog and pegvisomant combination therapy for acromegaly. |
2009-11-23 |
2023-08-12 |
Not clear |